INmune Bio, Inc.

NASDAQ:INMB

Biotechnology

Healthcare
$1.89 +8.38%

+$0.15 today

Market cap
$50.25M
Beta
0.98
P/E (TTM)
-1.1
EPS (TTM)
-$1.56
52W Low $1.09High $3.24

Volume 0.09M

Average 0.68M

Balance Sheet

Inspect the capital base behind the business.

Assets

$32.35M

FY 2025 · Annual

-18.2% YoY

Liabilities

$8.83M

FY 2025 · Annual

+18.2% YoY

Equity

$23.52M

FY 2025 · Annual

-26.7% YoY

Balance Sheet

USD
Metric
FY 2021
Dec 2021
FY 2022
Dec 2022
FY 2023
Dec 2023
FY 2024
Dec 2024
FY 2025
Dec 2025
Cash & Equivalents74.81M52.15M35.85M20.92M24.75M
Short-term Investments00000
Net Receivables5.5M8.46M2.44M1.41M4.54M
Inventory(5.5M)34K000
Other Current Assets5.5M(34K)1.51M331K595K
Total Current Assets82.61M64.68M39.94M22.66M29.89M
Property, Plant & Equipment (Net)726K507K414K307K914K
Goodwill00000
Intangible Assets16.51M16.51M16.51M16.51M0
Long-term Investments00000
Tax Assets00000
Other Non-current Assets99K99K131K79K1.55M
Total Non-current Assets17.34M17.12M17.06M16.9M2.46M
Total Assets99.95M81.8M57M39.56M32.35M
Account Payables3.8M5.21M7.9M6.56M7.79M
Short-term Debt72K5M9.92M00
Tax Payables00000
Deferred Revenue474K616K000
Other Current Liabilities(62K)9K524K517K0
Total Current Liabilities4.36M10.92M18.47M7.22M8.42M
Long-term Debt14.46M9.7M000
Deferred Tax Liabilities00000
Deferred Revenue (Non-current)00000
Other Non-current Liabilities199K550K000
Total Non-current Liabilities15.36M10.77M397K244K411K
Total Liabilities19.72M21.69M18.86M7.47M8.83M
Common Stock18K18K817K22K27K
Retained Earnings(63.72M)(91.01M)(121.02M)(163.1M)(209.04M)
Accumulated OCI1K(699K)(799K)(575K)(737K)
Other Stockholders Equity00000
Minority Interest00000
Total Equity80.23M60.1M38.14M32.1M23.52M
Total Debt15.23M15.31M10.44M384K1.03M
Net Debt(59.58M)(36.84M)(25.41M)(20.54M)(23.72M)

Balance Sheet

Assets, liabilities & equity

Cash & Equivalents$21.4M
Receivables$770.0K
Other Current$694.0K
Total Current Assets$22.8M
PP&E (Net)$2.3M
Other Non-current$683.0K
Total Non-current Assets$3.0M
Total Assets$25.8M

Analysis

Selected assets total $25.8M for Latest. The largest visible component is Cash & Equivalents at $21.4M, about 82.7% of the tab total. Use the mix to judge balance sheet concentration, liquidity, leverage, and how much of book value is supported by tangible operating assets.

Recent Filings

Recent regulatory filings

FilingDescriptionDate
3Initial statement of beneficial ownershipSep 23, 2026
4Statement of changes in beneficial ownershipSep 23, 2026
4Statement of changes in beneficial ownershipSep 17, 2026
3Initial statement of beneficial ownershipSep 16, 2026
8-KCurrent reportSep 14, 2026

How much cash does INMB have?

INmune Bio, Inc. (INMB) reported $24.75M in cash and equivalents in fiscal 2025.

How much debt does INMB carry?

INmune Bio, Inc. (INMB) reported $1.03M of total debt, with net debt of -$23.72M.